DDInter631 DDInter1435
Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Eltrombopag {u} (Compound) binds {v} (Gene) CYP2C8
Eltrombopag {u} (Compound) is included by {v} (Pharmacologic Class) Thrombopoietin Receptor Agonists
Eltrombopag {u} may cause a minor interaction that can limit clinical effects when taken with {v} Boceprevir
Eltrombopag {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Eltrombopag {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Simvastatin
Eltrombopag {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Eltrombopag {u} may lead to a major life threatening interaction when taken with {v} Peginterferon alfa-2b
Eltrombopag (Compound) binds CYP2C8 (Gene)
Eltrombopag (Compound) is included by Thrombopoietin Receptor Agonists (Pharmacologic Class)
Eltrombopag may cause a minor interaction that can limit clinical effects when taken with Boceprevir
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin
Eltrombopag may lead to a major life threatening interaction when taken with Berotralstat
Eltrombopag may lead to a major life threatening interaction when taken with Peginterferon alfa-2b